Pasteur Institute of India

What Pasteur Institute of India does

Pasteur Institute of India (PII) is a government autonomous institute established in 1907 in Coonoor, Tamil Nadu, operating under the Ministry of Health and Family Welfare, Government of India. It is registered as a society under the Societies Registration Act 1860 and runs on a no-profit-no-loss basis funded primarily by Grant-in-Aid from the central government. Its core business is manufacturing and supplying the DPT group of vaccines (DPT, DT, TT) and Tissue Culture Antirabies Vaccine (TCARV, Vero Cell Purified) to India's Universal Immunization Programme (UIP), with existing installed capacity of 85 million DPT-group doses targeted to expand to 130 million doses across 7 new and 2 modified GMP-compliant facilities.

The institute's technology stack centers on tissue-culture-based vaccine production using Vero cell lines, intradermal rabies vaccination protocols (4-dose regimen with anti-rabies immunoglobulin for Class III exposures), and CPCSEA-regulated laboratory animal breeding (Swiss Mice and Guinea Pigs) for in-house and external research supply. It also operates an on-site rabies treatment dispensary, a rabies diagnostic laboratory offering RFFIT antibody testing, and academic programs (M.Phil./Ph.D. in Microbiology, Biotechnology, Biochemistry; M.D. Microbiology) affiliated with Bharathiar University and Tamil Nadu Dr. M.G.R. Medical University. Distribution is entirely domestic, executed through direct supply to UIP, walk-in patient services, and credentialed CPCSEA institutes.

The commercial model is non-market: revenue is fundamentally government appropriations rather than commercial sales, pricing of vaccines is not publicly disclosed, and there are no active B2B/B2C marketing channels. The GTM motion is government-to-government for vaccines and direct-to-patient for rabies treatment, with ancillary fee-for-service revenue from laboratory animal sales and academic tuition. Customer concentration is effectively total for the core vaccine line, with the UIP/Government of India acting as both primary buyer and funding source.

Name

Pasteur Institute of India

Legal name

Pasteur Institute of India

Website

https://pasteurinstituteindia.in

Company type

Private

Founded year

1907

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Funding, Reimbursement & Vaccines-for-Children (VFC)/Public Purchase Programs (HLAJAHAK)

Keywords

• Vaccine manufacturing
• Rabies vaccine production
• Immunization programmes
• GMP vaccine facilities
• Government health services

Headquarters

HQ city

Coonoor

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Government Grant-in-Aid Funding: The institute functions on a no-profit no-loss basis, primarily funded through Grant-in-Aid from the Ministry of Health and Family Welfare, Government of India. Historical GIA data shows annual funding ranging from Rs. 3,600 lakhs to Rs. 6,850 lakhs across General, Salaries, Swachhta Action Plan, and Capital categories.
2. Laboratory Animal Sales: Sale of laboratory animals (Swiss Mice at Rs. 350 each, Guinea Pigs at Rs. 600-1000 each) to other CPCSEA registered institutes for research purposes. Payment via demand draft or NEFT/RTGS.
3. Vaccine Supply to UIP: Production and supply of DPT group vaccines and antirabies vaccine to the Universal Immunization Programme (UIP) and government health facilities across India

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Pasteur Institute of India manufactures the DPT group of vaccines (DPT, DT, TT) and Tissue Culture Antirabies Vaccine (TCARV) at GMP-compliant facilities for supply to India's Universal Immunization Programme. It also operates a Rabies Treatment Centre providing post-exposure prophylaxis and anti-rabies immunoglobulin to animal bite victims, a rabies diagnostic laboratory, supplies laboratory animals to CPCSEA-registered research institutes, and offers affiliated postgraduate academic programs.

Product overview

Pasteur Institute of India is a government vaccine manufacturing and research institute that produces a portfolio of essential vaccines for India's Universal Immunization Programme (UIP). The core products consist of the DPT group of vaccines (DPT, DT, and TT vaccines) and Tissue Culture Antirabies Vaccine (TCARV). The institute operates GMP-compliant manufacturing facilities and provides healthcare services including a Rabies Treatment Centre and Rabies Diagnostic Laboratory. Additionally, it supplies laboratory animals for research and offers academic programmes through university affiliations. The institute's mission focuses on producing safe, potent, and cost-effective vaccines with continuing improvement in quality systems.

Differentiator

Problem solved

Functional benefit

Products and services

• DPT Vaccine (Diphtheria-Pertussis-Tetanus Vaccine)

Quantifiable outcome

• 118 years of continuous operation in vaccine production and rabies treatment
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• Bharathiar University, CoimbatorecoreStrategic or Co-development PartnerAcademic partnership for conducting M.Phil. and Ph.D. courses in Microbiology, Biotechnology (Part time and Full time), and Biochemistry (Part time). The institute serves as a research center for doctoral programs affiliated with the university.
• Tamil Nadu Dr. M.G.R. Medical University, ChennaicoreStrategic or Co-development PartnerAcademic partnership for M.D. (Microbiology) program affiliated with the university. Provides postgraduate medical education opportunities in collaboration with the institute's research facilities.
• CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals)coreOthersRegulatory partnership for laboratory animal breeding and trading. Institute holds CPCSEA registration (66/Go/ReRcBt-S/R-L99/CPCSEA) for research and breeding in-house use and for trading purpose. Provides laboratory animals to other CPCSEA registered institutes.
• Ministry of Health and Family Welfare, Government of IndiacoreOthersParent ministry providing operational oversight, governance through Governing Body, and funding through Grant-in-Aid. The institute functions as an autonomous body under this ministry.

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Biological E: Hyderabad-headquartered vaccine manufacturer supplying DPT, TT, and other vaccines to India's UIP. Direct peer in the same government-tender-driven segment, with comparable product mix focused on pediatric immunization.
• Panacea Biotec: New Delhi-headquartered vaccine manufacturer with a strong DPT, DT, TT, and combination vaccine portfolio. Direct peer competing in the same UIP tenders and pediatric immunization product categories as PII.
• Bharat Biotech: Hyderabad-based vaccine and biotherapeutics manufacturer producing UIP vaccines and rabies vaccines. Direct competitor for government immunization contracts, with overlapping rabies and DPT-group portfolios and similar Indian public-sector customer base.
• Serum Institute of India: World's largest vaccine manufacturer by doses, headquartered in Pune. Directly comparable as a domestic supplier of DPT, rabies, and other UIP vaccines; competes with PII for the same government procurement tenders but at vastly greater scale and broader product portfolio.
• Haffkine Bio-Pharmaceutical Corporation: Maharashtra government-owned biopharmaceutical company producing vaccines and antisera. Direct comparable as another state/government-aligned Indian vaccine manufacturer with a legacy institutional structure and UIP supply mandate.
• Indian Immunologicals Limited (IIL): Hyderabad-based vaccine manufacturer under the National Dairy Development Board. Closely comparable in being a public-sector-aligned domestic vaccine producer with UIP exposure and a rabies vaccine franchise, sharing the same institutional/government customer profile as PII.

Others

• Hester Biosciences: Ahmedabad-based manufacturer focused on veterinary vaccines and animal health products. Comparable in the lab animal and veterinary-adjacent space PII supports through its CPCSEA-registered animal breeding facility, but operates on the animal-health rather than human-vaccine side.

Broad incumbents

• Sanofi Pasteur: Global vaccines division of Sanofi, one of the largest multinational vaccine manufacturers. Comparable as a rabies and pediatric vaccine producer at much broader scale; provides reference for international GMP standards PII benchmarks against.
• GSK Vaccines: Global vaccine major with established DTP-containing combination vaccines (e.g., Infanrix) and rabies products. Comparable as a broad incumbent operating in the same pediatric and rabies vaccine categories but with a much wider global portfolio.

Emerging players

• Zydus Cadila (Vaccines / Vebevaco): Indian pharma and biotech group with a growing vaccine portfolio (including COVID and rabies franchises). Partially comparable as a domestic manufacturer increasingly active in UIP-relevant pediatric and infectious disease vaccines.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pasteur-institute-of-india

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pasteur Institute of India